Success Story: From Biomedical Engineering to NIW Approval for a Researcher Advancing Personalized Neuromodulation
Client’s Testimonial:
"Thank you very much for the confirmation and for all your assistance throughout my EB2-NIW petition."
On August 9th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Research Fellow in the Field of Biomedical Engineering (Approval Notice).
General Field: Biomedical Engineering
Position at the Time of Case Filing: Postdoctoral Research Fellow
Country of Origin: Pakistan
State of Residence at the Time of Filing: Michigan
Approval Notice Date: August 9th, 2026
Processing Time: 21 months, 29 days (Premium Processing Upgrade Requested)
Case Summary:
“What does it take to successfully secure a National Interest Waiver, even after facing a Request for Evidence (RFE)?” In this case, it required showing how specialized expertise in biomedical engineering and related research areas could contribute to improved understanding, earlier detection, and more personalized treatment approaches for complex medical conditions.
North America Immigration Law Group is pleased to celebrate the approval of an I-140 NIW petition for a client holding a Ph.D. in biomedical engineering. The petition, which successfully overcame an RFE, connected the client’s objective research record and current U.S. university research role to an endeavor of substantial merit and national importance.
Advancing Personalized Treatment Through Biomedical Signal Analysis
The client’s proposed endeavor focuses on studying nerve signaling related to gastrointestinal function in order to improve understanding of digestive system disorders and support the development of more personalized and effective treatment approaches.
We demonstrated that this work addresses an important healthcare need by supporting improved diagnosis, advancing understanding of complex physiological systems, and contributing to the development of innovative treatment approaches. We also emphasized that the client’s work aligns with critical and emerging technology areas, including machine learning and neurotechnologies.
Contextualizing Objective Metrics for the Adjudicator
To show that the client was well positioned to advance the endeavor, we presented the following objective indicators:
- 8 peer-reviewed journal articles, including 5 first-authored articles and 1 co-first-authored article.
- 7 abstracts, including 3 first-authored abstracts and 1 first-authored preprint.
- 107 scholarly citations.
- At least 2 completed peer reviews.
- Research support connected to the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research, and the Canada Foundation for Innovation.
- 2 recommendation letters, including 1 independent advisory opinion. One expert noted:
"Given the influence that [Client’s] work has on academic research and industry applications, I am confident that he shall continue to produce works of equal or greater value."
The petition placed these metrics in context by showing that several of the client’s papers were cited at notably high rates, including 3 papers ranked among the top 10% and 1 paper ranked among the top 20% in Molecular Biology and Genetics for their publication years.
To demonstrate significance, we showed that independent researchers relied on the client’s work in later studies involving a range of studies related to autonomic nervous system function, physiological monitoring, gastrointestinal health, pain assessment, neural disorders, and gut-brain interactions.
The Result
This approved NIW petition presented a cohesive narrative connecting the client’s biomedical engineering background to the national need for improved diagnosis and personalized treatment of functional gastrointestinal disorders.
We congratulate the client on successfully navigating the RFE to secure this I-140 NIW approval and look forward to seeing the client’s continued contributions to biomedical engineering, gastrointestinal disorder research, machine learning-enabled signal analysis, and personalized neuromodulation technologies in the United States.